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Abstract 
BODY SIZE MISMATCH BETWEEN DONOR AND RECIPIENT IN CADAVERIC 
KIDNEY TRANSPLANTATION. 
LS Lee, LA Auersvald, EB Claus, MJ Bia, AL Friedman, MI Lorber, GP Basadonna. 
Department of Surgery, Division of Organ Transplantation and Immunology and 
Department of Internal Medicine, Division of Nephrology (MJB), Yale University School 
of Medicine, New Haven, CT. 
Recently much attention has focused on antigen independent mechanisms as 
major contributors to late renal allograft loss. Nephron under-dosing at the time of 
transplantation has been proposed to cause hyperfiltration and ultimately renal graft 
failure1. Kidney size and nephron number have been successfully correlated with body 
surface area (BSA)2'3. Using BSA as a proxy for nephron number, we investigated the 
relationship between matching donor and recipient BSA and cadaveric renal allograft 
survival. We studied the United Network of Organ Sharing renal transplant population in 
this retrospective study using logistic and Cox regression analyses as well as actuarial 
survival curves. These analyses revealed that a higher probability of graft failure was 
associated with younger non-white recipients, older non-white donors, increased creatinine 
at discharge, treatment for rejection before discharge, and a smaller BSA ratio of donor to 
recipient. Our results demonstrate that while body size matching does affect long-term graft 
survival, its effect is weaker than the more important determinants of long-term graft 
survival, like creatinine at discharge, episodes of acute rejection before discharge, 
recipient race, and recipient and donor age. Therefore, it does not appear that size matching 
will significantly decrease the incidence of long-term allograft loss in cadaveric renal 
transplantation. 
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Introduction 
With the advent of immunosuppressive drugs and improved post-transplant care, 
short-term patient and graft survival following renal transplantation has steadily 
improved over the past decade. One year graft survival rates range from 75% to over 
80%'. However, the rate of late graft loss after the first post-transplant year has remained 
unchanged1. Chronic rejection is the leading cause of late graft loss and accounts for 
24%-67% of this graft loss4-6. Other significant causes include patient death with a 
functioning transplant and noncompliance4'6. 
Clinically chronic rejection is characterized by a gradual decline in glomerular 
filtration rate, and is associated with proteinuria and hypertension after the first three or 
six months post-transplantation . Unlike with acute rejection, chronic rejection does not 
respond to increased amounts of immunosuppressives. Histologically chronic rejection 
may resemble acute rejection or grafts with no apparent dysfunction with mild to 
moderate tissue infiltration by T cells and macrophages. In addition, chronic rejection is 
characterized by vascular, glomerular, and tubulointerstitial lesions7. 
Both immunologic and nonimmunologic factors have been implicated in late renal 
allograft loss. Evidence supporting immune mediated mechanisms of late graft loss 
include the greater frequency of chronic rejection in recipients of cadaveric rather than 
living-related transplants9, the association of acute rejection with the development of 
chronic rejection10’11, and the possible connection between chronic rejection and 
inadequate immunosuppression secondary to noncompliance or concerns of the 
nephrotoxic side effects of cyclosporine-A11. Several hypotheses have been proposed to 
explain the immunologic basis for chronic rejection. CD4+ T helper cells coordinate the 
immune response among the antigen presenting cells, macrophages, cytotoxic T cells, 
and B cells through the release of cytokines. It is well known that two types of CD4+ T 
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helper cells exist: TH1 clones which produce IFN-y and TNF-(3 leading to macrophage 
and cytotoxic T cell activity and TH2 clones whose cytokines promote antibody 
production1-. One hypothesis proposes that chronic rejection is the result of numerous 
acute rejection episodes mediated by TH1 activated macrophages and cytotoxic T cells. 
Another hypothesis argues that immunosuppression of TFi 1 cells leads to the dominance 
of TH2 cells, which predominantly cause antibody-mediated graft damage leading to 
chronic rejection. Whether chronic rejection results from a cellular or humoral mediated 
mechanism, the target vascular antigen appears to be endothelial cells. Early vascular 
rejection is correlated with late graft loss; i.e., the five year graft survival rate in this 
group is 34% compared to 70% to 75% survival in patients never experiencing acute 
rejection or having only interstitial rejection on biopsy7. 
Recently much attention has focused on potential nonimmunologic factors 
contributing to late graft loss. These include glomerular hyperfiltration, nephron dosing, 
renal ischemic injury, systemic hypertension, hyperlipidemia, and drug toxicity. In many 
animal models of renal injury, the adaptive changes of glomerular hyperfiltration and 
hypertension have been shown to contribute to the progression of renal damage13. 
Glomerular hyperfiltration and hypertension may lead to glomerulosclerosis and loss of 
renal function. 
Nephron dosing refers to the concept that when the metabolic demands exceed the 
limit imposed by the nephron number, renal fibrosis is more likely to occur13. Loss of 
renal mass leads to adaptive changes, including an increase in size and function of the 
remaining nephrons. Animal models have demonstrated that a decrease in renal mass 
may lead to proteinuria and glomerulosclerosis14-17. Clinical evidence exists to support 
the nephron dosing hypothesis. Long-term graft survival of kidneys from donors that are 
older (>50 years old), younger (<6 years old), or female and obese recipients is 
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decreased18’19. Conflicting evidence exists regarding the impact of donor-recipient body 
size mismatch on long-term graft survival20'23. 
Delayed graft function due to renal ischemic injury occurs in 25% to 50% of 
cadaveric transplant recipients13. Long-term graft survival is decreased in recipients with 
delayed graft function24. Both immunologic as well as nonimmunologic mechanisms 
may explain the contribution of delayed graft function to late graft loss. Studies have 
shown that ischemia leads to the upregulation of class-II antigen expression on renal 
endothelial cells, making the kidney more antigenic25. In addition, loss of renal mass 
from ischemic injury leads to hyperfiltration and renal dysfunction. 
Systemic hypertension has been negatively correlated with graft survival26. In 
patients with chronic rejection, the degree of hypertension has been shown to correlate 
with the severity of histologic change and the rate of decline of renal function. Few 
studies have addressed the efficacy of the various antihypertensives in reducing the rate 
of late graft loss. However, calcium-channel blockers are the agents of choice post¬ 
transplant because they also reduce cyclosporine-induced nephrotoxicity. Angiotensin¬ 
converting-enzyme inhibitors are used with caution because the combination with 
cyclosporine has been shown to lead to acute renal failure15. 
Pretransplant hyperlipidemia is a risk factor for late graft loss7. Oxidatively 
modified LDL enhances a patient’s immune response13, and LDL is directly toxic to 
endothelial cells7. Although renal damage itself may lead to the lipid abnormalities, 
studies showing the presence of apolipoproteins in the vessel wall of grafts with chronic 
rejection and vascular intimal hyperplasia in patients with pretransplant 
hypercholesterolemia suggest that hyperlipidemia leads to graft atherosclerosis7’13. 
Cyclosporine induces interstitial fibrosis by both causing ischemic damage from 
chronic vasoconstriction and directly activating interstitial matrix formation13. Lower 
doses of cyclosporine have been shown to cause an initial but not progressive decline in 
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glomerular filtration rate13. However, too low doses of cyclosporine can lead to increased 
rates of acute and chronic rejection11. 
In this study we investigated the impact of the nonimmunologic factor of nephron 
dosing on late renal allograft loss. We characterized a nationwide cadaveric renal 
transplant patient population with respect to body size matching and examined the 
relationship between donor/ recipient BSA ratio and renal allograft loss. 
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Statement of Purpose 
We intend to answer the question, ‘does body size matching affect long-term renal 
allograft survival?’ using a retrospective study to investigate 25,092 patients from the 
United Network of Organ Sharing (UNOS) Scientific Renal Transplant Registry. 
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Methods 
Data regarding 25,092 patients who underwent cadaveric renal transplantation 
between October 1, 1987 and December 31, 1993 were obtained from the UNOS 
Scientific Renal Transplant Registry. Among them, 3039 patients experienced graft loss 
and the 22,053 patients who maintained good graft function at last follow-up were used 
as controls. Descriptive statistics were performed by donor/ recipient status for cases and 
controls using means and percentages. Differences in demographic and clinical variables 
between cases and controls by donor/ recipient status were assessed using t-tests and chi- 
square tests for continuous and binary variables, respectively. The independent variable 
of interest, body surface area ratio (BSR), was defined as BSA donor/ BSA recipient 
where BSA was calculated according to the following formula (Costeff’s rule): BSA (m2) 
= (4*weight (kg) + 1)1 (90+weight)27. Additional independent variables included age, 
gender, and race of recipient and donor as well as creatinine of recipient at discharge, 
number of transplants, and treatment for rejection before discharge. 
The outcome variable, renal graft loss, was analyzed both as a binary variable 
(graft loss/ no graft loss) and as a continuous variable (time to graft loss). Logistic 
regression was used to measure the effect of BSR on the probability of graft loss while a 
Cox proportional hazards model was used to measure the impact of BSR on the time to 
graft loss. The logistic and Cox regression models provided unadjusted odds ratios and 
relative risks, respectively, with 95% confidence. Significant variables associated with 
allograft loss on univariate analysis were incorporated into a multivariate model to obtain 
adjusted odds ratios and relative risks. Multivariate analyses were conducted using the 
stepwise selection procedure with entry and exit criteria set at p=Q.05. 
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Initially the effect of BSR on graft loss and time to graft loss was examined with 
BSR as a continuous variable. To obtain a more clinically meaningful odds ratio, BSR 
was also redefined by pairs of binary dummy variables. These variables allowed 
comparison of graft loss rates among four categories of BSR: 0-0.80, 0.81-1.50, 1.51- 
1.80, and >1.80 with 0-0.80 as the baseline category. These cut points were selected 
based upon the distribution of graft loss rates by BSR grouping (Figure 1). 
Kaplan-Meier curves and log-rank tests were used to compare the renal graft 
survival curves of patients in the four different BSR groups. Renal graft survival was also 
analyzed by subgrouping the recipients by gender and race. 
Data are expressed as means ± SE. All analyses were performed using PC-SAS 
version 6.05. 
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Figure 1. Proportion of Graft Loss in BSA ratio 
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Results 
Recipient characteristics are shown in Table 1. Control and case recipients were 
well matched for gender only while the donors for the controls and cases were 
significantly different regarding each of the demographic variables. Mean BSA ratio for 
all recipients was 1.00 ±0.002. The mean difference in BSA between the paired donor 
and recipient of the controls was 0.036 ± 0.003. This was significantly different from that 
between the paired donor and recipient of the cases (0.098 ± 0.008). Therefore, the 
controls were better size-matched than the cases. Median number of days of follow-up 
was 687 days by which time 78.6% (2389) of the 3039 graft losses had occurred. By the 
first 400 days post-transplantation, 47% of the graft losses had occurred. At five years the 
number of recipients without graft failure and remaining in follow-up was 105. 
Univariate analyses of the variables revealed that recipient age and race, donor 
age, gender, and race, creatinine at discharge, number of transplants, treatment for 
rejection before discharge, and BSA ratio all had a significant effect on graft loss (Tables 
2, 3). Recipients with a BSA ratio <0.8 had a 1.479 greater risk of graft loss compared to 
those with a BSA ratio >0.8. Similar results were obtained with the multivariate logistic 
and Cox analyses (Tables 2, 3). A higher probability of renal graft loss was associated 
with the younger, non-white recipient treated for rejection before discharge with a high 
discharge creatinine and a BSA ratio <0.8 who receives a renal graft for the second or 
third time from an older, non-white, female donor. The most important determinants of 
graft failure were creatinine at discharge, treatment for rejection before discharge, and 
recipient age and race. Although a relatively weak risk factor for graft loss, BSA ratio 
was more important than donor age and race (donor race and transplant number in the 
Cox regression model). Only donor gender (and number of transplants in the logistic 
model) was not a significant risk factor for graft loss in the multivariate analyses. 
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Table 1. Donor and Recipient Characteristics 
Control Case 
recipient donor recipient donor 
mean age 42.2 ±0.09* 30.7 ±0.1 1* 39.2 ±0.25* 32.6 ±0.32* 
male / female 61 / 39 64/36* 60 / 40 60 / 40* 
white / non-white 75 /25* 89/11* 63 / 37* 86/ 14* 
mean creatinine at discharge 2.27 ±0.01* 3.31 ±0.05* 
treated for rejection before 
discharge (N/Y) 
3.0* 1.8* 
1° / retransplant 19.0* 15.7* 
mean D/R BSA ratio 1.01 ±0.002* 0.98±0.007* 
* p value <0.05 

Table 2. Logistic Regression: Graft Loss (n=25,092) 
Univariate Multivariate 
Independent variable p value* Odds ratio (95% 
Confidence Interval) 
p value** Odds ratio (95% 
Confidence Interval) 
creatinine at discharge 0.0001 1.180(1.163, 1.198) 0.0001 1.148 (1.130, 1.165) 
treated for rejection 
before discharge (Y/N) 
0.0001 1.688 (1.558, 1.828) 0.0001 1.571 (1.448, 1.705) 
recipient race 
(non-white vs. white) 
0.0001 1.722 (1.590, 1.864) 0.0001 1.519 (1.397, 1.651) 
recipient age 0.0001 0.984 (0.981,0.987) 0.0001 0.983 (0.980, 0.986) 
D/R BSA ratio 0.0001 1.451 (1.258, 1.675) 0.0001 1.541 (1.342, 1.715) 
D/R BSA ratio group 
(<0.8 vs. >0.8) 
0.0001 1.479 (1.344, 1.631) 0.0001 1.567 (1.404, 1.751) 
donor age 0.0001 1.007 (1.005, 1.010) 0.0001 1.009 (1.006, 1.012) 
donor race 
(non-white vs. white) 
0.0001 1.365 (1.223, 1.523) 0.0002 1.237 (1.102, 1.388) 
number of transplants 
(retransplant vs. 1 °) 
0.0027 1.262 (1.084, 1.469) - - 
donor gender 
(female vs. male) 
0.0001 1.208 (1.118, 1.306) 0.0481 1.088 (1.001, 1.182) 
* p value< 0.05 
** p value< 0.006 
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Table 3. Cox Regression: Graft Loss (n= 25,092) 
Univariate Multivariate 
Indepencient variable p value* Risk ratio (95% 
Confidence Interval) 
p value** Risk ratio (95% 
Confidence Interval) 
creatinine at discharge 0.0001 1.070 (1.065, 1.075) 0.0001 1.062 (1.056, 1.068) 
recipient race 
(non-white vs. white) 
0.0001 1.657 (1.540, 1.783) 0.0001 1.519 (1.416, 1.646) 
treated for rejection 
before discharge (Y/N) 
0.0001 1.581 (1.468, 1.703) 0.0001 1.535 (1.425, 1.653) 
recipient age 0.0001 0.987 (0.985,0.990) 0.0001 0.987 (0.984, 0.989) 
donor age 0.0001 1.009 (1.007, 1.01 1) 0.0001 1.012 (1.010, 1.015) 
D/R BSA ratio 0.0001 1.468 (1.281, 1.683) 0.0001 1.676 (1.534, 1.841) 
D/R BSA ratio group 
(<0.8 vs. >0.8) 
0.0001 1.449 (1.325, 1.584) 0.0001 1.585 (1.436, 1.750) 
donor race 
(non-white vs. white) 
0.0001 1.396(1.262, 1.545) 0.0001 1.313 (1.183, 1.457) 
number of transplants 
(retransplant vs. 1°) 
0.0001 1.321 (1.148, 1.520) 0.0010 1.270(1.102, 1.463) 
donor gender 
(female vs. male) 
0.0001 1.215 (1.130, 1.306) 0.0393 1.084 (1.004, 1.171) 
* p value< 0.05 
** p value< 0.006 
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Recipients in the BSA ratio group >0.8 had a significantly higher 5 year actuarial 
graft survival rate than recipients with a BSA ratio <0.8 (controls: 78%, cases: 74%) 
(Figure 2). The difference in survival rate between the two patient groups remained 
around 4% throughout the entire 5 year period studied. Similar results were obtained 
when 5 year actuarial graft survival rates were compared for patients with extreme BSA 
ratios (group 1: <0.5, group 2: 0.95-1.05, group 3: >1.5). The 5 year graft survival rate of 
group 1 was 4% lower than the other 2 groups (p<0.05). Analyses of recipients first 
subdivided according to race or gender and then by BSA ratio group revealed the same 
results. There was also a significant effect on graft survival by race alone. 
The recipients were reanalyzed after removing those patients who had lost their 
renal grafts within the first year post-transplantation. Recipients who lost their grafts 
were younger with more non-whites, a higher mean creatinine at discharge, and more 
treatment for rejection before discharge than the control recipients (p<0.05). The gender 
distribution and mean BSA ratio for the two recipient groups were not significantly 
different. The donors for the recipients who lost the grafts were older with more non¬ 
whites (p<0.05). Multivariate analyses revealed similar results as with all the patients 
(Tables 4, 5). However, the Kaplan-Meier actuarial graft survival curves did not show a 
significant difference in survival rates between recipients with a small (<0.8) versus a 
large (>0.8) BSA ratio. 
There were 1814 transplantations from pediatric donors <10 years of age. Of 
these, 1616 recipients had a BSA ratio <0.8 while the other 198 had a BSA ratio >0.8. 
There was no difference in the 5 year graft survival rates for the two BSA ratio groups. 
However, these recipients of pediatric kidneys had a 2% lower graft survival rate at five 
years than recipients with adult donors (p<0.05). 
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Figure 2. Survival of Kidney Grafts according to BSA ratio 
p = 0.0001 
-O' BSA ratio <0.8 
BSA ratio >0.8 
Years Post-transplant 

Table 4. Logistic Regression: Graft Loss >lyear post-transplantation (n=23237) 
Multivariate 
Independent variable p value* Odds ratio (95% 
Confidence Interval) 
recipient race (non-white vs. white) 0.0001 2.349 (2.085, 2.647) 
recipient age 0.0001 0.973 (0.969, 0.978) 
donor age 0.0001 1.009 (1.005, 1.013) 
treated for rejection before discharge (Y/N) 0.0001 1.296 (1.140, 1.473) 
D/R BSA ratio group (<0.8 vs. >0.8) 0.0019 1.311 (1.105, 1.556) 
creatinine at discharge 0.0052 1.030 (1.009, 1.051) 
* p<Q.Q06 
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Table 5. Cox regression: Graft Loss >1 year post-transplantation (n=23237) 
Multivariate 
Independent variable p value* Risk ratio (95% 
Confidence Interval) 
recipient race (non-white vs. white) 0.0001 2.341 (2.084, 2.630) 
recipient age 0.0001 0.977 (0.973, 0.981) 
donor age 0.0001 1.015 (1.01 1, 1.019) 
creatinine at discharge 0.0001 1.039 (0.883, 1.057) 
D/R BSA ratio group (<0.8 vs. >0.8) 0.0001 1.374 (1.167, 1.617) 
treated for rejection before discharge (Y/N) 0.0073 1.183 (1.046, 1.338) 
donor race (non-white vs. white) 0.0231 1.217 (1.027, 1.442) 
number of transplants (retransplant vs. 1 ) 0.0370 1.285 (1.015, 1.625) 
* p value< 0.006 
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Discussion 
Long-term renal allograft survival remains unchanged despite tremendous 
advances in immunosuppression and post-transplant care. Recently much attention has 
been focused on antigen independent mechanisms as major contributors to late renal 
allograft loss. Rat models, including Shimamura and Morrison's five-sixths nephrectomy 
model14, Hostetter and colleagues’ eleven-twelths model28, and Brenner and associates’ 
five-sixths model15, have all demonstrated the deleterious effect of nephron dosing on 
long-term renal graft survival. Reductions in nephron mass to one-sixth accelerated the 
development of proteinuria and glomerulosclerosis regardless of the immunogenicity of 
the transplanted organ15. Leaving a native kidney in the transplanted rats protected them 
from these changes16. Furthermore, expression of cell surface molecules, cytokine 
production, and infiltration of macrophages in renal tissue was modulated by nephron 
mass17. 
Several natural and man-made experiments in human beings exist that assess the 
nephron dosing hypothesis. These models include unilateral renal agenesis, unilateral 
nephrectomy for renal disease, and donor nephrectomy. Unilateral renal agenesis is 
associated with an increased incidence of proteinuria and focal segmental 
glomerulosclerosis. Long-term follow-up of patients with unilateral nephrectomy 
secondary to renal disease or donor status failed to demonstrate these adverse outcomes. 
However, proteinuria and focal segmental glomerulosclerosis occurred in patients with a 
single kidney who further underwent between 25% and 75% nephrectomy of this solitary 
kidney for renal carcinoma29. 
Clinical evidence exists to suggest a link between nephron dosing and long-term 
graft outcome. Diminished graft survival is associated with donors who are aged 4 to 6, 
older (>50), female, black, or cadaveric, obese recipients (> 100kg), and kidneys that 
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experienced rejection episodes18’19’30. The ideal experiment to demonstrate the impact of 
nephron dosing on long-term graft survival in human beings would replicate the animal 
studies by comparing single versus double kidney transplants. However, this is hardly 
feasible given the grave disparity between the supply and demand for kidneys. No 
prospective data exist. Therefore, we were limited to a retrospective study of single 
kidney recipients. 
Several retrospective studies have examined the impact of donor/ recipient size 
matching on long-term graft survival. Kupin and colleagues found lower donor/ recipient 
BSA ratios (0.8810.1) in recipients with transplant glomerulopathy than in those with 
normal graft function (1.010.2). However, the former recipients had other reasons to 
develop graft failure, including 84% being African American who were poorly HLA 
matched with multiple episodes of acute rejection-0. The ratio of donor kidney weight to 
recipient body weight did not impact graft survival in over 300 patients studied by Roth 
and co-workers-1. Miles and associates studied over 150 patients using the ratio of renal 
volume to recipient BSA and found no effect on graft survival22. Similarly, the variable 
of interest, the ratio of donor/ recipient BSA, for Gaston and colleagues did not affect 
graft survival and renal function as measured by serum creatinine levels23. 
Our study is the largest to date and may explain the different results obtained from 
Roth et al., Miles et al., and Gaston et al. The studies to date examining the effect of 
donor/ recipient size matching suggest that whatever impact nephron dosing has on long¬ 
term renal allograft survival is overshadowed by other clinical parameters. Our study 
confirms these findings. We have demonstrated that the donor/ recipient BSA ratio of 
cadaveric renal transplants in the United States does have a statistically significant impact 
on long-term allograft loss. However, its effect is weak compared to the most important 
determinants of long-term graft survival like creatinine at discharge, episodes of acute 
rejection, and recipient race. These results were duplicated when we analyzed only the 
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patients with a graft surviving for at least one year post-transplantation. In comparing the 
four categories of BSA ratio, recipients with a BSA at least 20% larger than their donors 
fared worse than the recipients with a smaller BSA in both the multivariate regression 
and survival analyses. The former recipients experienced a 4% lower survival rate which 
remained constant throughout the 5 year follow-up. This absolute value, while 
statistically significant, was not impressive. In the nephron dosing hypothesis, one may 
expect the survival curves to diverge over the years as the allograft loses more nephrons. 
This was not seen in our analyses using the four original as well as the three extreme 
BSA ratio categories. 
In examining the patient population, the majority of recipients were already well 
size matched. Although the difference in mean BSA ratios between the controls and cases 
was statistically significant, the absolute values revealed a negligible difference (controls: 
1.01, cases: 0.98). Similarly, while the mean difference in BSA between the pairs of 
donors and recipients for the controls versus the cases was significantly different, the 
actual numbers were not impressive (controls: 0.036, cases: 0.098). However, the trend of 
these values with the recipients experiencing graft loss being slightly larger than their 
donors and more poorly size matched with their donors than the control recipients 
supports the idea that recipients with a smaller nephron dose are more likely to develop 
late graft failure. 
In this retrospective study using donor/ recipient BSA ratio as a surrogate for 
nephron dosing, we demonstrate that while body size matching does affect cadaveric 
renal allograft survival up to 5 years post-transplantation, its effect is overshadowed by 
other clinical factors. Therefore, it does not appear that prospective size matching will 
significantly decrease the incidence of late allograft loss in cadaveric renal transplant 
recipients. 
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